検索 条件検索
wx_img
Inquiry Form
  1. Home
  2. Govorestat

Govorestat

Applied Therapeutics announced FDA acceptance and priority review of new drug application for Govorestat for the treatment of classic galactosemia. Govorestat is a central nervous system (CNS) penetrant Aldose Reductase Inhibitor (ARI) in development for the treatment of several rare neurological diseases, including Galactosemia, SORD Deficiency, and PMM2-CDG.

4-(methoxycarbonyl)thiophene-3-carboxylic acid
4-(methoxycarbonyl)thiophene-3-carboxylic acid
CM465295
4282-30-8
methyl 4-[3-(tert-butoxy)-3-oxopropanoyl]thiophene-3-carboxylate
methyl 4-[3-(tert-butoxy)-3-oxopropanoyl]thiophene-3-carboxylate
CM1075463
2170729-43-6
tert-butyl 2-{4-oxo-3H,4H-thieno[3,4-d]pyridazin-1-yl}acetate
tert-butyl 2-{4-oxo-3H,4H-thieno[3,4-d]pyridazin-1-yl}acetate
CM1075464
2170729-41-4
3-Amino-4-mercaptobenzotrifluoride hydrochloride
3-Amino-4-mercaptobenzotrifluoride hydrochloride
CM158051
4274-38-8
2-Chloromethyl-5-trifluoromethyl-benzothiazole
2-Chloromethyl-5-trifluoromethyl-benzothiazole
CM157389
110704-50-2